意大利 - 意大利文 - Ministero della Salute

cutera inc. - dispositivi per chirurgia con generatore a radiofrequenza - altri

意大利 - 意大利文 - myHealthbox

effik italia - etinilestradiolo e drospirenone - compressa rivestita con film - compresse gialle (attive):0,03 mg etinilestradiolo e 3 mg drospirenone. compresse bianche (placebo): nessun principio attivo - progestinici ed estrogeni, combinazioni fisse - contraccezione orale

意大利 - 意大利文 - myHealthbox

effik italia - etinilestradiolo e drospirenone - compressa rivestita con film - compresse rosa (attive): 0,02 mg etinilestradiolo e 3 mg drospirenone. compresse bianche (placebo): nessun principio attivo - progestinici ed estrogeni, combinazioni fisse - contraccezione orale

欧盟 - 意大利文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cobicistat, atazanavir - infezioni da hiv - antivirali per uso sistemico - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 e 5.

欧盟 - 意大利文 - EMA (European Medicines Agency)

teva pharma b.v. - leflunomide - artrite, reumatoide - immunosoppressori - leflunomide è indicato per il trattamento di pazienti adulti con artrite reumatoide attiva come "farmaco antireumatico modificante la malattia" (dmard). recenti o in trattamento concomitante con epatotossici o haematotoxic dmards (e. metotrexato) può comportare un aumento del rischio di reazioni avverse gravi; pertanto, l'inizio del trattamento con leflunomide deve essere attentamente considerato per quanto riguarda questi aspetti benefici / rischi. inoltre, il passaggio da leflunomide ad un altro dmard, senza seguire la procedura di washout può anche aumentare il rischio di gravi reazioni avverse, anche per lungo tempo dopo la commutazione.

欧盟 - 意大利文 - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasie colorettali - antineoplastic agents, protein kinase inhibitors - stivarga è indicato come monoterapia per il trattamento di pazienti adulti con:metastatico del colon-retto (crc) che sono stati trattati in precedenza o che non sono considerati candidati per, terapie disponibili - questi includono fluoropyrimidine a base di chemioterapia, la terapia anti-vegf e di una terapia anti-egfr;non resecabile o metastatico, i tumori stromali gastrointestinali (gist) che ha attuato o che sono intolleranti ad un precedente trattamento con imatinib e sunitinib;carcinoma epatocellulare (hcc) che sono stati precedentemente trattati con sorafenib.

欧盟 - 意大利文 - EMA (European Medicines Agency)

serono europe limited - efalizumab - psoriasi - immunosoppressori - trattamento di pazienti adulti affetti da moderata a grave psoriasi a placche cronica che non hanno risposto a, o che presentano controindicazioni o che sono intolleranti ad altre terapie sistemiche, inclusi ciclosporina, metotressato e puva (vedere sezione 5. 1 - efficacia clinica).

欧盟 - 意大利文 - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplasie dello stomaco - agenti antineoplastici - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

欧盟 - 意大利文 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedema, ereditario - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

欧盟 - 意大利文 - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).